Literature DB >> 22822712

Dried blood spots and sparse sampling: a practical approach to estimating pharmacokinetic parameters of caffeine in preterm infants.

Parul Patel1, Hussain Mulla, Venkatesh Kairamkonda, Neil Spooner, Sonya Gade, Oscar Della Pasqua, David J Field, Hitesh C Pandya.   

Abstract

AIMS: Dried blood spots (DBS) alongside micro-analytical techniques are a potential solution to the challenges of performing pharmacokinetic (PK) studies in children. However, DBS methods have received little formal evaluation in clinical settings relevant to children. The aim of the present study was to determine a PK model for caffeine using a 'DBS/microvolume platform' in preterm infants.
METHODS: DBS samples were collected prospectively from premature babies receiving caffeine for treatment of apnoea of prematurity. A non-linear mixed effects approach was used to develop a population PK model from measured DBS caffeine concentrations. Caffeine PK parameter estimates based on DBS data were then compared with plasma estimates for agreement.
RESULTS: Three hundred and thirty-eight DBS cards for caffeine measurement were collected from 67 preterm infants (birth weight 0.6-2.11 kg). 88% of cards obtained were of acceptable quality and no child had more than 10 DBS samples or more than 0.5 ml of blood taken over the study period. There was good agreement between PK parameters estimated using caffeine concentrations from DBS samples (CL = 7.3 ml h⁻¹  kg⁻¹; V = 593 ml kg⁻¹; t(½) = 57 h) and historical caffeine PK parameter estimates based on plasma samples (CL = 4.9-7.9 ml h⁻¹  kg⁻¹; V = 640-970 ml kg⁻¹; t(½) = 101-144 h). We also found that changes in blood haematocrit may significantly confound estimates of caffeine PK parameters based on DBS data.
CONCLUSIONS: This study demonstrates that DBS methods can be applied to PK studies in a vulnerable population group and are a practical alternative to wet matrix sampling techniques.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 22822712      PMCID: PMC3575947          DOI: 10.1111/j.1365-2125.2012.04392.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  25 in total

1.  Use of dried blood spots in drug development: pharmacokinetic considerations.

Authors:  Malcolm Rowland; Gary T Emmons
Journal:  AAPS J       Date:  2010-04-10       Impact factor: 4.009

2.  The effect of hematocrit on assay bias when using DBS samples for the quantitative bioanalysis of drugs.

Authors:  Philip Denniff; Neil Spooner
Journal:  Bioanalysis       Date:  2010-08       Impact factor: 2.681

3.  Validation of individual quantitative methods for determination of cytochrome P450 probe substrates in human dried blood spots with HPLC-MS/MS.

Authors:  Rakesh Lad
Journal:  Bioanalysis       Date:  2010-11       Impact factor: 2.681

4.  Can finger-prick sampling replace venous sampling to determine the pharmacokinetic profile of oral paracetamol?

Authors:  Baba S Mohammed; Garry A Cameron; Lindsay Cameron; Gabrielle H Hawksworth; Peter J Helms; James S McLay
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

5.  Dried blood spots as a sample collection technique for the determination of pharmacokinetics in clinical studies: considerations for the validation of a quantitative bioanalytical method.

Authors:  Neil Spooner; Rakesh Lad; Matt Barfield
Journal:  Anal Chem       Date:  2009-02-15       Impact factor: 6.986

6.  Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics.

Authors:  Iftekhar Mahmood
Journal:  J Pharm Sci       Date:  2010-07       Impact factor: 3.534

7.  A sensitive genotyping assay for detection of drug resistance mutations in reverse transcriptase of HIV-1 subtypes B and C in samples stored as dried blood spots or frozen RNA extracts.

Authors:  Carrie Ziemniak; Allison George-Agwu; William J Moss; Stuart C Ray; Deborah Persaud
Journal:  J Virol Methods       Date:  2006-07-07       Impact factor: 2.014

8.  Population pharmacokinetics of caffeine in premature neonates.

Authors:  A C Falcão; M M Fernández de Gatta; M F Delgado Iribarnegaray; D Santos Buelga; M J García; A Dominguez-Gil; J M Lanao
Journal:  Eur J Clin Pharmacol       Date:  1997       Impact factor: 2.953

9.  Use of DBS sample collection to determine circulating drug concentrations in clinical trials: practicalities and considerations.

Authors:  Neil Spooner; Y Ramakrishnan; M Barfield; O Dewit; S Miller
Journal:  Bioanalysis       Date:  2010-08       Impact factor: 2.681

10.  Topiramate concentrations in neonates treated with prolonged whole body hypothermia for hypoxic ischemic encephalopathy.

Authors:  Luca Filippi; Giancarlo la Marca; Patrizio Fiorini; Chiara Poggi; Giacomo Cavallaro; Sabrina Malvagia; Domenico E Pellegrini-Giampietro; Renzo Guerrini
Journal:  Epilepsia       Date:  2009-09-10       Impact factor: 5.864

View more
  13 in total

Review 1.  Pharmacokinetic studies in infants using minimal-risk study designs.

Authors:  Julie Autmizguine; Daniel K Benjamin; P Brian Smith; Mario Sampson; Philippe Ovetchkine; Michael Cohen-Wolkowiez; Kevin M Watt
Journal:  Curr Clin Pharmacol       Date:  2014

2.  Enhanced stability of blood matrices using a dried sample spot assay to measure human butyrylcholinesterase activity and nerve agent adducts.

Authors:  Jonas W Perez; Brooke G Pantazides; Caroline M Watson; Jerry D Thomas; Thomas A Blake; Rudolph C Johnson
Journal:  Anal Chem       Date:  2015-05-20       Impact factor: 6.986

Review 3.  Dosing in neonates: special considerations in physiology and trial design.

Authors:  Lawrence C Ku; P Brian Smith
Journal:  Pediatr Res       Date:  2014-09-30       Impact factor: 3.953

4.  Developmental Pharmacokinetics and Age-Appropriate Dosing Design of Milrinone in Neonates and Infants with Acute Kidney Injury Following Cardiac Surgery.

Authors:  Tomoyuki Mizuno; Katja M Gist; Zhiqian Gao; Michael F Wempe; Jeffrey Alten; David S Cooper; Stuart L Goldstein; Alexander A Vinks
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

5.  Salivary caffeine concentrations are comparable to plasma concentrations in preterm infants receiving extended caffeine therapy.

Authors:  Nicole R Dobson; Xiaoxi Liu; Lawrence M Rhein; Robert A Darnall; Michael J Corwin; Betty L McEntire; Robert M Ward; Laura P James; Catherine M T Sherwin; Timothy C Heeren; Carl E Hunt
Journal:  Br J Clin Pharmacol       Date:  2016-06-03       Impact factor: 4.335

6.  An observational study of blood concentrations and kinetics of methyl- and propyl-parabens in neonates.

Authors:  H Mulla; S Yakkundi; J McElnay; I Lutsar; T Metsvaht; H Varendi; G Nellis; A Nunn; J Duncan; H Pandya; M Turner
Journal:  Pharm Res       Date:  2014-09-19       Impact factor: 4.200

Review 7.  Advances in Instrumental Analysis of Brominated Flame Retardants: Current Status and Future Perspectives.

Authors:  Mohamed Abou-Elwafa Abdallah
Journal:  Int Sch Res Notices       Date:  2014-10-28

8.  Prediction of pharmacokinetic values of two various dosages of caffeine in premature neonates with apnea.

Authors:  Fatemeh Faramarzi; Mohammadreza Shiran; Mohammadreza Rafati; Roya Farhadi; Ebrahim Salehifar; Maryam Nakhshab
Journal:  Indian J Pharmacol       Date:  2021 Mar-Apr       Impact factor: 1.200

9.  Predictive performance of a gentamicin population pharmacokinetic model in neonates receiving full-body hypothermia.

Authors:  Mario R Sampson; Adam Frymoyer; Benjamin Rattray; C Michael Cotten; P Brian Smith; Edmund Capparelli; Sonia L Bonifacio; Michael Cohen-Wolkowiez
Journal:  Ther Drug Monit       Date:  2014-10       Impact factor: 3.118

10.  Geneva cocktail for cytochrome p450 and P-glycoprotein activity assessment using dried blood spots.

Authors:  M Bosilkovska; C F Samer; J Déglon; M Rebsamen; C Staub; P Dayer; B Walder; J A Desmeules; Y Daali
Journal:  Clin Pharmacol Ther       Date:  2014-04-10       Impact factor: 6.875

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.